These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
262 related items for PubMed ID: 16637456
1. [Complications of heparin administration]. Matýsková M, Buliková A. Vnitr Lek; 2006 Mar; 52 Suppl 1():92-7. PubMed ID: 16637456 [Abstract] [Full Text] [Related]
2. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Harr T, Scherer K, Tsakiris DA, Bircher AJ. Allergy; 2006 Jun; 61(6):787-8. PubMed ID: 16677252 [No Abstract] [Full Text] [Related]
3. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Jappe U. Blood Coagul Fibrinolysis; 2006 Nov; 17(8):605-13. PubMed ID: 17102645 [Abstract] [Full Text] [Related]
4. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Casele HL. Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684 [Abstract] [Full Text] [Related]
5. Adverse effects of heparin. Alban S. Handb Exp Pharmacol; 2012 Dec; (207):211-63. PubMed ID: 22566227 [Abstract] [Full Text] [Related]
6. The effects of heparin and low molecular weight heparins on bone. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. Thromb Res; 2008 Dec; 122(3):293-8. PubMed ID: 17716711 [Abstract] [Full Text] [Related]
7. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404 [Abstract] [Full Text] [Related]
8. The use of low-molecular-weight heparins in pregnancy--how safe are they? Deruelle P, Coulon C. Curr Opin Obstet Gynecol; 2007 Dec; 19(6):573-7. PubMed ID: 18007136 [Abstract] [Full Text] [Related]
9. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521 [No Abstract] [Full Text] [Related]
11. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Koch P. Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697 [Abstract] [Full Text] [Related]
12. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Nelson-Piercy C. Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):489-509. PubMed ID: 9488788 [Abstract] [Full Text] [Related]
17. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [Abstract] [Full Text] [Related]